Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
J Am Vet Med Assoc ; 213(3): 374-6, 1998 Aug 01.
Article in English | MEDLINE | ID: mdl-9702226

ABSTRACT

Acromegaly was diagnosed in 3 cats with insulin-resistant diabetes mellitus (DM) on the basis of history and physical examination findings, which ruled out other causes of insulin-resistant DM, and by documenting high plasma concentrations of growth hormone. Computed tomography revealed a mass in the area of the pituitary gland in each cat. Pituitary gland tumors were irradiated with cobalt 60, and none of the cats developed complications to radiotherapy. Each cat received a total dose of 48 Gy of cobalt 60 during 12 treatments. After completion of radiotherapy, insulin requirements were less for all cats, although in 1 cat, this improvement was transient. Diabetes mellitus resolved in 2 of 3 cats. After treatment, decreases in insulin requirements correlated with decreases in plasma growth hormone concentrations in 2 of 3 cats in which DM resolved. On the basis of these findings, irradiation of pituitary gland tumors appears to be a treatment option for cats with acromegaly.


Subject(s)
Acromegaly/veterinary , Adenoma/veterinary , Cat Diseases/radiotherapy , Pituitary Neoplasms/veterinary , Acromegaly/etiology , Acromegaly/radiotherapy , Adenoma/complications , Adenoma/radiotherapy , Animals , Blood Glucose/analysis , Brain/diagnostic imaging , Cat Diseases/etiology , Cats , Cobalt Radioisotopes/therapeutic use , Diabetes Complications , Diabetes Mellitus/drug therapy , Diabetes Mellitus/veterinary , Female , Growth Hormone/blood , Hypoglycemic Agents/therapeutic use , Insulin Resistance , Insulin, Long-Acting/therapeutic use , Male , Pituitary Neoplasms/complications , Pituitary Neoplasms/radiotherapy , Tomography, X-Ray Computed/veterinary
2.
J Vet Intern Med ; 12(1): 1-6, 1998.
Article in English | MEDLINE | ID: mdl-9503353

ABSTRACT

Medical records of 104 cats with diabetes mellitus were reviewed. Information from 54 cats that had multiple blood glucose concentrations evaluated at least 5 times over a minimum of 3 months, beginning at the time insulin treatment was initiated, was used to evaluate the efficacy of insulin in treating diabetes mellitus. Fourteen of 54 cats were treated with protamine zinc insulin (PZI), 26 with ultralente insulin, and 14 with lente insulin. Six, 29, and 19 cats had good, mediocre, and poor glycemic control, respectively, based on mean blood glucose concentrations, whereas 31, 21, and 2 owners thought clinical response was good, mediocre, and poor, respectively. No significant difference was found in glycemic control among cats treated with PZI, ultralente, or lente insulin. Glycemic control was significantly (P < .05) better in 33 cats without than in 21 cats with concurrent disease. All 104 cats were used to calculate survival data. Fifty-one of 104 cats were alive at the time of the study. Mean (+/- standard deviation [SD]) and median survival times were 24 (+/- 16) and 20 months, respectively, in the 51 cats still alive at the end of the evaluation, and 25 (+/- 4) and 17 months, respectively, in the 53 cats that had died during the period of evaluation. Pancreatic abnormalities identified in 37 cats that underwent necropsy included chronic pancreatitis (n = 17), acute to subacute pancreatitis (n = 2), exocrine pancreatic adenocarcinoma (n = 7) and adenoma (n = 1), islet cell atrophy and vacuolar degeneration (n = 27), and islet amyloidosis (n = 8). No association was found between glycemic control and islet amyloidosis or exocrine pancreatic neoplasia, or between survival time and chronic pancreatitis, islet amyloidosis, or exocrine pancreatic neoplasia. In conclusion, diabetic cats evaluated in this study showed a variable response to exogenously administered insulin, ranging from excellent to poor. By maintaining mean blood glucose concentrations under 300 mg/dL, clinical signs were improved, and owners were satisfied with insulin treatment. Concurrent potentially insulin-antagonistic diseases were common and deleteriously affected glycemic control and survival time.


Subject(s)
Cat Diseases/drug therapy , Diabetes Mellitus/veterinary , Hypoglycemic Agents/therapeutic use , Insulin/therapeutic use , Animals , Blood Glucose/analysis , Blood Glucose/drug effects , Cat Diseases/mortality , Cats , Diabetes Mellitus/drug therapy , Diabetes Mellitus/mortality , Hypoglycemic Agents/administration & dosage , Insulin/administration & dosage , Insulin, Long-Acting/administration & dosage , Insulin, Long-Acting/therapeutic use , Retrospective Studies , Survival Analysis , Time Factors
3.
J Am Vet Med Assoc ; 212(3): 374-6, 1998 Feb 01.
Article in English | MEDLINE | ID: mdl-9470046

ABSTRACT

OBJECTIVE: To determine efficacy of cobalt 60 radiotherapy in dogs with pituitary-dependent hyperadrenocorticism (PDH) that have detectable tumors but no neurologic abnormalities. DESIGN: Case series. ANIMALS: 6 dogs with PDH that had a detectable pituitary mass on magnetic resonance images. PROCEDURE: Radiation was delivered in 11 fractions during a 3.5-week period for a total dose of 44 Gy. Clinical signs were evaluated, a urinalysis and ACTH stimulation test were performed, and urine cortisol-to-creatinine ratio and plasma endogenous ACTH concentration were measured before, immediately after, and 1, 3, 6, 9, and 12 months after radiotherapy. Magnetic resonance imaging was repeated 1 year after radiotherapy. RESULTS: Clinical signs of hyperadrenocorticism resolved in 3 dogs but recurred in 2 of the 3. Clinical condition of 2 dogs improved but did not return to normal. One dog did not improve. Results of ACTH stimulation tests and urine cortisol-to-creatinine ratios correlated with clinical signs. Plasma endogenous ACTH concentration transiently decreased in all 6 dogs. One year after radiotherapy, size of tumors was decreased by 25% in 2 dogs; in the other 4 dogs, tumors could no longer be detected. None of the dogs developed neurologic abnormalities. Adverse effects of radiotherapy were mild. CLINICAL IMPLICATIONS: Radiotherapy did not result in adequate control of clinical signs of hyperadrenocorticism in 5 of 6 dogs, but size of pituitary tumors was dramatically reduced. Thus, it may be reasonable to recommend radiotherapy in dogs with PDH that have pituitary tumors for which greatest vertical height is 8 mm or more.


Subject(s)
Adrenocortical Hyperfunction/veterinary , Dog Diseases/radiotherapy , Pituitary Irradiation/veterinary , Pituitary Neoplasms/complications , Adrenocortical Hyperfunction/etiology , Adrenocortical Hyperfunction/radiotherapy , Animals , Cobalt Radioisotopes/therapeutic use , Dog Diseases/etiology , Dogs , Female , Magnetic Resonance Imaging/veterinary , Male , Pituitary Neoplasms/diagnosis
4.
Vet Q ; 19(2): 81-4, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9225438

ABSTRACT

Primary hyperparathyroidism (PHP) is an infrequently diagnosed disorder in cats. In this report the signs and symptoms of two cats with hypercalcaemia due to PHP are described, together with diagnostic approach, results of treatment, and immunohistochemical findings. A 9-year-old and a 13-year-old neutered male domestic shorthair cat were presented with signs of lethargy, anorexia, and vomiting. Both cats had persistent hypercalcaemia and normo- to hypophosphataemia. Cytological examination of a fine-needle aspiration biopsy sample of a palpable cervical mass revealed groups of benign glandular-epithelial cells in one cat. In the other cat no cervical mass was palpable. In this cat plasma parathyroid hormone (PTH) levels were measured repeatedly and these values exceeded the maximum reference value on two occasions. Following exclusion of other causes of hypercalcaemia both cats were subjected to neck surgery and in both a solitary parathyroid adenoma was removed. The adenomas contained an abundance of PTH, as demonstrated by immunohistochemical techniques. Plasma calcium and phosphate concentrations returned to within, reference ranges postoperatively. Recovery was uncomplicated and there were no signs of recurrence on follow-up examinations.


Subject(s)
Cat Diseases/physiopathology , Hyperparathyroidism/veterinary , Adenoma/pathology , Adenoma/veterinary , Animals , Cats , Hypercalcemia/veterinary , Hyperparathyroidism/physiopathology , Male , Parathyroid Neoplasms/pathology , Parathyroid Neoplasms/veterinary
5.
Domest Anim Endocrinol ; 12(4): 355-62, 1995 Oct.
Article in English | MEDLINE | ID: mdl-8575168

ABSTRACT

In dogs and humans, the measurement of urinary corticoid excretion has become a standard screening test for the diagnosis of hyperadrenocorticism. Mainly because the urinary excretion of cortisol was considered to be very low in cats, its measurement was not used in the diagnosis of hyperadrenocorticism in this species. We therefore studied the urinary excretion of [3H]cortisol and measured the corticoid/creatinine (C/C) ratio in healthy cats and in cats with hyperadrenocorticism in order to evaluate the applicability of this measurement in the diagnosis of feline hyperadrenocorticism. The median urinary excretion of intravenously administered [3H]cortisol was 1.85% (measured as excreted 3H; range, 1.56 to 1.99; n = 4). High-performance liquid chromatography analysis showed a small peak of cortisol and a large peak consisting primarily of conjugates of cortisol and/or its metabolites. The 2.5 and 97.5 percentiles of the urinary C/C ratio in healthy cats were 2 x 10(-6) to 36 x 10(-6) (n = 42). The C/C ratio was significantly higher in six cats with pituitary-dependent hyperadrenocorticism (median, 122 x 10(-6); range 51 x 10(-6) to 272 x 10(-6)). The administration of a high dose of dexamethasone (0.1 mg/kg thrice daily per os) led to marked suppression of the C/C ratio in healthy cats (median suppression of the average of the C/C ratio of the first two consecutive days was 92%; range, 74 to 96%; n = 12), as well as in five cats with pituitary-dependent hyperadrenocorticism.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Adrenocortical Hyperfunction/veterinary , Cat Diseases/diagnosis , Cats/urine , Glucocorticoids/urine , Adrenocortical Hyperfunction/diagnosis , Adrenocortical Hyperfunction/urine , Animals , Cat Diseases/urine , Chromatography, High Pressure Liquid , Creatinine/urine , Dexamethasone/pharmacology , Dose-Response Relationship, Drug , Female , Glucocorticoids/pharmacology , Hydrocortisone/urine , Male , Radioimmunoassay , Reference Values , Tritium
6.
J Vet Intern Med ; 9(5): 361-5, 1995.
Article in English | MEDLINE | ID: mdl-8531185

ABSTRACT

Central diabetes insipidus was diagnosed by vasopressin measurements during hypertonic stimulation in a 9-year-old male giant Schnauzer with polyuria and polydipsia. The impaired release of vasopressin was believed to be caused by a large pituitary tumor, which was visualized by computed tomography. Studies of the function of the anterior lobe and the pars intermedia of the pituitary gland were conducted, and high concentrations of ACTH and alpha-melanotrophic hormone (alpha-MSH) were found without concomitant hyperadrenocorticism. Studies of the molecular size of the immunoreactive ACTH in plasma by gel filtration revealed that most of the circulating immunoreactivity was not ACTH but its precursor pro-opiomelanocortin (POMC) and low-molecular-weight POMC-derived peptides. The pituitary tumor of this dog probably originated from melanotrophic cells of the pars intermedia. The sensitivity of the pituitary-adrenocortical system for the suppressive effect of dexamethasone was unaffected.


Subject(s)
Diabetes Insipidus, Nephrogenic/veterinary , Dog Diseases/etiology , Pituitary Neoplasms/veterinary , Pro-Opiomelanocortin/metabolism , Adrenocortical Hyperfunction/veterinary , Animals , Diabetes Insipidus, Nephrogenic/etiology , Dog Diseases/metabolism , Dogs , Male , Pituitary Neoplasms/complications , Pituitary Neoplasms/diagnostic imaging , Pituitary Neoplasms/metabolism , Radiography
SELECTION OF CITATIONS
SEARCH DETAIL
...